Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094099 | 0.92 | HTR2C (0.39) | HTR2CEHMT2KDM4EALDH1A1CLK2 | |
| SCHEMBL6092478 | 0.87 | TP53 (0.39) | KDM4EALDH1A1ROCK2ROCK1MEN1 | |
| SCHEMBL8251851 | 0.86 | HTR2C (0.43) | HTR2CCLK2CLK3DYRK1ABUB1 | |
| SCHEMBL6092473 | 0.85 | EHMT2 (0.38) | HTR2CEHMT2KDM4EALDH1A1 | |
| SCHEMBL6094237 | 0.85 | MAPT (0.41) | KDM4EALDH1A1ROCK2ROCK1MEN1 | |
| SCHEMBL8584124 | 0.83 | KMT2A (0.45) | HTR2CKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL6094319 | 0.81 | HTR2C (0.40) | HTR2CCLK2DYRK1ABUB1MAPT | |
| SCHEMBL6092120 | 0.81 | GSK3B (0.41) | KDM4EALDH1A1ROCK2ROCK1MEN1 | |
| SCHEMBL6091806 | 0.80 | HTR2C (0.53) | HTR2CBUB1 | |
| SCHEMBL6092499 | 0.80 | HTR2C (0.53) | HTR2CBUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | GABRB2, GABRB1, GABRB3 | HTR2C 227/4885EHMT2 3534/4885KDM4E 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.